LEADER 01977oam  2200457Ia 450 
001 9910698954603321
005 20090820090806.0
035   $a(CKB)5470000002398329
035   $a(OCoLC)421097512
035   $a(EXLCZ)995470000002398329
100   $a20090702d2008      ua             0
101 0 $aeng
135   $auran|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aGuidance for industry$b[electronic resource] $epostmarketing adverse event reporting for medical products and dietary supplements during an influenza pandemic
210  1$aRockville, MD :$cU.S. Dept. of Health and Human Services, Food and Drug Administration, Office of Counterterrorism and Emerging Threats :$cCenter for Drug Evaluation and Research :$cCenter for Biologics Evaluation and Research :$cCenter for Devices and Radiological Health :$cCenter for Food Safety and Applied Nutrition,$d[2008]
215   $a1 online resource (12 pages)
300   $a"Draft guidance".
300   $a"Procedural".
300   $a"December 2008".
517   $aGuidance for industry 
606   $aDrugs$xSide effects$xReporting$xGovernment policy$zUnited States
606   $aDietary supplements$xGovernment policy$zUnited States
606   $aInfluenza
615  0$aDrugs$xSide effects$xReporting$xGovernment policy
615  0$aDietary supplements$xGovernment policy
615  0$aInfluenza.
712 02$aUnited States.$bFood and Drug Administration.$bOffice of Counterterrorism and Emerging Threats.
712 02$aCenter for Drug Evaluation and Research (U.S.)
712 02$aCenter for Biologics Evaluation and Research (U.S.)
712 02$aCenter for Devices and Radiological Health (U.S.)
712 02$aCenter for Food Safety and Applied Nutrition (U.S.)
801  0$bGPO
801  1$bGPO
801  2$bGPO
906   $aBOOK
912   $a9910698954603321
996   $aGuidance for industry$93434577
997   $aUNINA